Baseball Daily Digest
KemPharm's stock soars after ADHD drug trial meets primary endpoints
Shares of KemPharm Inc. KMPH, +4.65% shot up 13% in premarket trade Monday after the specialty pharmaceutical company said a trial of its treatment of ADHD in patients between the ages of 6 and 12 (KP415) met primary and secondary efficacy ...
KemPharm (KMPH) Says KP415.E01 Efficacy and Safety Trial in Children With ADHD Met Primary Endpoint
KemPharm, Inc. (KMPH)'s Stock Is Sell After Forming